To combine the therapeutic effects of IR and the radiosensitizing properties of Ru1, in this study we utilise PLGA nanoparticles to co-deliver 111In-labelled hEGF and Ru1 to oesophageal cancer cells that overexpress EGFR, demonstrating both a combinational effect and molecular targeting for this novel therapeutic combination. The gene discussed is SFMBT1; the disease is carcinoma of esophagus.